Ankylosing Spondylitis
Conditions
Keywords
Ankylosing Spondylitis, Umbilical Cord/placenta-Derived MSC, Transplantation
Brief summary
The purpose of this study is to evaluate the safety and efficacy of mesenchymal stem cells (MSCs) derived from human umbilical cord/placenta at a dose of 1.0E+6 MSC/kg in subject for the therapy of Ankylosing spondylitis (AS)
Detailed description
Ankylosing spondylitis (AS) is a chronic, progressive inflammatory rheumatic disease involving primarily the sacroiliac joints and the axial skeleton. The main clinical features are back pain and progressive stiffness of the spine. Oligoarthritis of the hips and shoulders, enthesopathy, and anterior uveitis are common, and involvement of the heart and lungs is rare. The current understanding of the pathogenesis of this disorder is limited.It mainly about to hereditary susceptibility (eg hla-b27),infection and autoimmunity. Although traditional drugs, such as Nonsteroidal antiinflammatory drugs (NSAIDs) disease-modifying antirheumatic drugs (DMARDs such as MTX,SASP OR thalidomide) and steroids have been used in the treatment of AS, however, many studies have indicated that the overall response to these drugs is not satisfied. Addition, the severe side effects of these drugs have also been observed. The management of AS patients therefore remains unsatisfactory and targeted therapies are needed. Human MSCs isolated from human umbilical cord/placenta have been shown to have immunoregulatory, immunosuppressive, stimulating hematopoiesis and tissue repairing properties. This study will evaluate the safety and effectiveness of MSC transplantation in the AS patients. This study will last 2 to 3 years. Participants will be randomly assigned to receive either MSC transplant +DMARDs therapy (experimental group) or DMARDs therapy (control group). Patients will undergo MSC transplant at the start of the study on Day 0. After 3 months, patients will receive the second MSC transplantation. After six and twelve months from the first transplantation, patients will be evaluated.
Interventions
BIOLOGICALHuman umbilical cord-derived MSCs
1.0E+6 MSC/kg, IV drop and repeat repeated after three months
Sponsors
Shandong University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
1. Patient age 18\ 60 years old with plan to infuse MSCs. 2. Diagnosis of Definite AS (arthritis of the spine) as defined by the modified New York criteria 3. Stable doses of sulfasalazine,methotrexate,thalidomide,hydroxychloroquine, low-dose corticosteroids, and NSAIDs are permitted 4. Patients must have an ECOG 0\ 2. 5. No moderate or sever organ dysfunction: Ejection fraction\>45%; Creatinine \<176 umol/L. 6. No severe infection. 7. Each patient must sign written informed consent.
Exclusion criteria
1. Other serious concomitant diseases (uncontrolled/severe kidney, liver, haematological, gastrointestinal, endocrine, cardiovascular, pulmonary, neurological or cerebral disease) 2. Psychiatric condition that would limit informed consent. 3. HIV, hepatitis B or C, tuberculosis, other infections 4. Positive Pregnancy Test or lactation 5. Patient has enrolled another clinical trial study within last 4 weeks. 6. Contraindications to MSC
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Assessment of Spondyloarthritis International Society (ASAS)20 response | 1 year | ASAS measures symptomatic improvement in AS patients.ASAS=4 domains:patient global assessment of disease activity,pain,function,inflammation.ASAS 20=20% improvement(vs.baseline)and an abosolute change≥1 units on a 0-10 scale(0=no disease activity;10=high disease activity)for ≥3 domains,and no worsening in remaining domain. Patient global Pain Function (as measured by the Bath Ankylosing Spondylitis Functional Index - BASFI) Inflammation (mean of the Bath Ankylosing Spondylitis Disease Activity Index - BASDAI question 5 and 6) |
| erythrocyte sedimentation rate (ESR) | 1 year | erythrocyte sedimentation rate (ESR) level will be mainly observed after transplanting 3, 6,12-month. |
| imageology | 1 year | imageology will be mainly observed after transplanting 3, 6,12-month. |
| C-reactive protein (CRP) | 1 year | C-reactive protein (CRP) level will be mainly observed after transplanting 3, 6,12-month. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of systemic T regulatory cell population | 1 year | Percentages of T regulatory cell population in peripheral blood will be tested in every 3 months after transplanting MSCs for one year |
| Side effects | 1 year | Side effects were observed after the treatment |
Countries
China
Contacts
Primary Contactchengyun zheng, Ph. D
Outcome results
None listed